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our article1 and inquiring questions regarding chronic pain
after angioembolization and surgical procedures.
In our study, we are reporting patients with acute retro-
peritoneal hemorrhagewithunderlying renal angiomyolipoma
(AML) with mean of 10-month follow-up. Answer to the
question, specifically “pain”, all patients had acute flank pain
at presentation, following angioembolization, flank pain
subsided within few days. During follow-up, our patients did
not experience recurrence of symptoms and in other words,
patients were pain free. However, we may need a longer
period of follow-up to answer the question of “lumbar chronic
pain”. Natural history of AML is poorly understood. Never-
theless, we do not think endovascular treatment leading to
lumbar chronic pain, rather recurrent symptoms, including
pain may result from AML re-growth or new focus of AML,
especially underlying conditions such as Tuberous sclerosis.2
Both endovascular treatment and laparoscopic partial
nephrectomy are the minimally invasive treatments in
managing renal AML.1e4 We agree angioembolization is the
first line treatment for patients with renal AMLs and re-
growth and long term results remain uncertain. To answer
the question of “the role of open or laparoscopic enucle-
ation of the residual mass vs. endovascular treatment in
preventing the lumbar chronic pain” may require multi-
center clinical trials with a larger number of patients.
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In Response to Prof. M.J. Gough’s Second Comment1
on SCAMICOS2
In SCAMICOS the power calculation was made separately
for the FemPopBK and FemDist groups with regard to one-
year follow-up but all randomised patients and all avail-
able follow-up data were reported and all information
from 98% of the randomised patients were used in the
analysis. It was clearly stated in the paper that we did not
achieve the planned power in the FemDist part of the
study and that there still is a possibility (in spite of
a negative result) that a vein cuff in this position might
give a clinically relevant advantage or disadvantage
regarding primary patency at three years. The number of
patients at risk as regards primary patency in the FemDist
group at three years was indeed only 13. However, Prof.
Gough’s argument with respect to primary patency at
three years from other studies appears somewhat brittle
as the number of patients at risk in the second JVRG’s
publication3 with distal anastomosis to the popliteal artery
below knee was 13 and in the two referred non-rando-
mised studies4,5 with distal anastomosis at mixed levels 14
and 9, respectively. Finally, the ‘balanced opinion’ sug-
gested by Prof. Gough is still only based on one rando-
mised study where 20 randomised patients appears to
have been excluded from the final report, and which did
not include any bypasses to the crural vessels but only to
the popliteal artery below knee.6References
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